| Objective: CD105 is the specific membrane receptor of TGF-B1 and TGF-B3, and it highly expresses on the surface of endothelial cells in those tissues with angiogenesis, such as granuloma, embryonic tissues, psoriasis and tumor tissues. CD105 becomes a particular marker in formed and unformed endothelial cells of angiogenesis. CD105 takes part in some steps of angiogenesis, and this suggests it maybe close correlate with the growth and progress of tumors. Multiple factor analysis shows that by using anti-CD105 monoclonal antibody E9, the microvascular density (MVD) could be an independent prognosis marker of breast cancer, gastric cancer and large intestine cancer. Animal experiments manifested that inject Mab E9 could effectively inhibit the growth of tumors. Immune and radio-immune therapy of tumors by using Mab E9 is under the stage of experimental investigation. Gene technique also used to prevent the formation of CD105 on surface of endothelial cells in tumor tissues, so that could inhibit angiogenesis. CD105 shows satisfactory developing prospect in diagnosis, prognosis and therapy of tumor. This experiment mainly aimed at detecting the expression and distribution of CD105 in normal tissues by using Mab E9, and compared the expression of CD105 with other pan-endothelial cell markers, such as CD34 and VIII-RA in normal tissues. At the same time, we also discuss the application and the value of CD105 in clinic therapy. Methods: 50 cases of autopsy specimens were collected include 6 cases fetus, 6 cases neonates and 38 cases adults. The expression of CD34, CD105 and VI1-RA in heart tissues, liver tissues, spleen tissues, lung tissues, kidney tissues, cerebrum tissues and umbilical core tissues were detected by Immunohistochemistry. Results: 1. The expression of the same endothelial cell marker had no significant difference between adults and children in the same organ (P>0.05). 2. There are significant differences between the expressions of the three EC markers in different organs (P<0. 01). 3. There is a notable significance between the expressions of CD105 Mab E9on micro and small blood vessels in different organs (P<0. 05). There is no significant difference between the expressions of CD34 Mab on micro and small blood vessels in the same organ (P>0.05) except for the brain tissue (P<0. 01). There is significant difference between the expressions of VIII on micro and small blood vessels of the liver, spleen and kidney (P<0.05) and no significance on the tissues of the brain, heart and lung (P>0.05). 4. There are notable differences between the expressions of CD105, CD34 and VIII on the EC of micro vessels of the same organ (P<0.01). From these comparisons we found that the positive rate of micro vessel endothelial cells marked by CD105 was higher than that by CD34 in the tissues of brain, heart, liver, spleen, lung and kidney. The expression of CD105 and VIII-RA on microvessels also has significant difference in those tissues (P<0.01) but heart (P>.05). There was no significant difference of CD34 and VIII-RA exsiting on microvessels in those tissues (P>0.05) but heart (P<0.01). Conclusions: 1. Mice anti-human CD105 monoclonal antibody E9 widely expressed on the surface of endothelial cells of human heart tissues, liver tissues, spleen tissues, lung tissues, kidney tissues, and cerebrum tissues. The prospect of using CD105 into anti-angiogenesis therapy in tumor is still need more study. 2. Mab E9 could stain stronger and had more reactive activity on micro blood vessels than small blood vessels. 3. CD105 had obviously superiority in detecting microvessels than pan-endothelial cell markers, such as CD34 and VIII-RA. |
PDF Full Text Request